Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds BLUE.
No tracked institution reports a position in BLUE as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-12-13 | 1-for-20reverse |
No one on the platform has traded BLUE yet.
No recent Form 4 filings on EDGAR β either no insider transactions reported recently or this isn't a SEC-registered issuer.
Stocks to Watch Tomorrow π§βπ»π§βπ«π Longs πππ Reliance Bel Eternal Shorts πππ Bluestar Shree cem Tcs π Disc - Do Your analysis also before Taking Trades $blue
View on StockTwits β@jlemx really seeing this work with Armstice onboard. Hedge funds doing this king of thing is becoming normalized. BP may now e thinking about this. They did this for $BLUE .
View on StockTwits β$CRDF I've been involved in few shit-show, gone sideways, type biotechs ( $BLUE $ITRM to name a few) in all those cases, I've NEVER seen a insider step up and buy shares - a sure sign they were in the death spiral. But here? We've got the CEO and a senior board member buying close to $1 Million in shares. They have to know something the rest of us pee-ons don't.
View on StockTwits β$BLUE $CXAI $LIMN $VMAR donβt sleep the rocket has blasted LIMN about to reach the moon
View on StockTwits β$LIMN $CXAI $VMAR $BLUE $LIMN β Donβt sleep on the setup. ππ₯ Fear creates opportunities, and small-cap biotech is where sentiment can flip fast. LIMN is positioned in the oncology space with a pipeline focused on next-generation cancer therapies, while strategic financing efforts provide a path toward advancing development. The market cap leaves room for significant moves when catalysts hit, and a reclaim of key resistance levels with volume could bring momentum back quickly. π Strong science + biotech upside + low valuation = a setup worth watching. The crowd usually notices after the move starts. π Do your own research. High risk, high reward. #LIMN #Biotech #CancerResearch #SmallCaps
View on StockTwits β$BLUE https://www.bizjournals.com/boston/news/2026/07/09/meet-new-bluebird-genetix.html
View on StockTwits β$BLUE any word on if they hit any of their benchmarks?
View on StockTwits β@PLX_BULLS $BLUE had some 200 ? 300? M debt ... $SGMO is debt free ... has much more pipeline and platforms , IP
View on StockTwits β$BLUE $CRSP $QQQ $QURE $SPY And so dumb, BLUE was bought out 2 years ago for 300M ..all done there !
View on StockTwits β$BLUE $QURE this @MF_DOOM character is a options player ..believe nothing he says β¦he has been here before touting higher prices and leaves when this hits $30 ..( use to be $25 ) so his rhetoric is garbageβ¦
View on StockTwits β$QURE go long kid, I was thinking BO around $80-100 but we may not even need a BO for that price point to be obtainable now but I do still think a BO is possible and on the table here in the long termβ¦letβs see as more time passes $BLUE $CRSP $SPY $QQQ
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $409M | +172.9% | $-8.56 | $-8.56β$-8.56 | β | 1 |
| 2027 | $277M | -32.3% | $-6.86 | $-6.86β$-6.86 | β | 1 |
| 2028 | $333M | +20.2% | $-1.56 | $-1.56β$-1.56 | β | 1 |
| 2029 | $415M | +24.6% | $-0.46 | $-0.46β$-0.46 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-14 | $-3.94 | $-2.66 | +32.5% |
| 2025-03-27 | $-3.60 | $-23.74 | -559.4% |
| 2024-11-14 | $-7.28 | $-6.20 | +14.8% |
| 2024-09-13 | $-0.40 | $-15.60 | -3800.0% |
| 2024-05-09 | $-0.49 | $0.21 | +142.9% |
| 2024-03-26 | $-0.66 | $-0.75 | -13.1% |
| 2023-11-07 | $-13.80 | $-13.20 | +4.3% |
| 2023-08-08 | $-14.40 |
| $-13.40 |
| +6.9% |
| $54M |
| β |
| MGTAMagenta Therapeutics, Inc. | $0.70 | -7.74% | $42M | β |
| PSTIPluristem Therapeutics Inc. | $1.00 | -2.91% | $41M | β |
Source: Financial Modeling Prep Β· peers by sector/industry